Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PRHSX vs. IXJ: which is better?

Bottom line

PRHSX vs IXJ: the short answer

PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 70% by weight.

But PRHSX is far broader, holding 279 positions to 124 for IXJ, so beyond the top names it adds exposure IXJ doesn't have.

IXJ is cheaper at 0.38% vs 0.83% — a difference of $45 a year per $10,000 invested.

Over five years, IXJ returned +6.4% a year vs +4.2% for PRHSX.

Updated Nov 19, 2026

PRHSX vs IXJ side by side

PRHSXIXJ
TypeMutual fundETF
Fund familyT. Rowe PriceiShares
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.83%0.38%
Annual cost per $10k$83$38
10-yr cost on $10k (prospectus)$1,025$480
Max front load—None
12b-1 fee—0%
1-yr return+17.7%+14.9%
5-yr return (annualized)+4.2%+6.4%
10-yr return (annualized)+9.1%+8.2%
Best quarter+23.5%+13.6%
Worst quarter−15.8%−11.8%
Net assets (fund)$11.9B$3.8B
Number of holdings279124
Portfolio turnover62%2%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPRHSXIXJDifference
2025+17.7%+14.9%+2.9%
2024+1.8%+0.6%+1.2%
2023+3.1%+3.5%−0.4%
2022−12.2%−4.7%−7.5%
2021+13.3%+19.5%−6.2%
2020+30.1%+12.5%+17.6%
2019+29.1%+23.4%+5.8%
2018+1.2%+2.9%−1.6%
2017+28.0%+20.3%+7.6%
2016−10.4%−6.2%−4.2%

Source: Fund prospectus bar charts

Holdings overlap

16 of PRHSX's top 25 holdings also appear in IXJ's top 25.

Shared top holdings
HoldingPRHSXIXJ
Eli Lilly & Co14.28%10.93%
Johnson & Johnson6.63%7.04%
Unitedhealth Group Inc5.99%4.40%
Abbvie Inc5.10%5.12%
Merck & Co. Inc.4.01%4.12%
Gilead Sciences Inc2.82%2.04%
Thermo Fisher Scientific Inc2.52%2.42%
Vertex Pharmaceuticals Inc2.28%1.64%
Bristol-myers Squibb Co2.11%1.53%
Abbott Laboratories1.89%2.05%
Intuitive Surgical Inc1.87%1.83%
Amgen Inc1.82%2.54%
Stryker Corp1.78%1.41%
Elevance Health Inc1.53%1.09%
Danaher Corp1.43%1.56%

Source: SEC Form N-PORT

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

IXJ top 10

  1. Eli Lilly And Company — 10.93%
  2. Johnson & Johnson — 7.04%
  3. Abbvie Inc. — 5.12%
  4. Unitedhealth Group Incorporated — 4.40%
  5. Merck & Co., Inc. — 4.12%
  6. Astrazeneca Plc — 3.76%
  7. Roche Holding AG — 3.75%
  8. Novartis AG — 3.71%
  9. Amgen Inc. — 2.54%
  10. Thermo Fisher Scientific Incorporated — 2.42%

FAQ

What is the difference between PRHSX and IXJ?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 70% by weight. But PRHSX is far broader, holding 279 positions to 124 for IXJ, so beyond the top names it adds exposure IXJ doesn't have.
Which is cheaper, PRHSX or IXJ?
IXJ has the lower expense ratio (0.38%).
Should I own both PRHSX and IXJ?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.